Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 repeat-dose ND-L02-s0201 in Japanese subjects with advanced hepatic fibrosis
jRCT2080222907Phase 1
- Sponsor
- Nitto
- Start
- Jul 2015
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ND-L02-s0201 in hepatic fibrosis, sponsored by Nitto. Primary endpoints: Safety and tolerability of ND-L02-s0201, Biological activity of ND-L02-s0201 and 1 more.
02
Drugs
ND-L02-s0201
03
Conditions
hepatic fibrosis
Beyond the preview
Go deeper on jRCT2080222907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222907.